Company: IMRX
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077655
Chunk: 45

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: S-3
Chunk 45
---
 success in clinical development versus traditional drug development approaches. Our pipeline also includes a discovery program targeting RAS, an undisclosed target, and other small molecule drug discovery programs.

#### Corporate Information
The mailing address for our principal executive office is 245 Main Street, Second Floor, Cambridge, MA 02142 and our telephone number is (617) 500-8080. Our website address is www.immuneering.com . The information contained in or accessible from our website is not incorporated into this prospectus supplement, and you should not consider it part of this prospectus supplement. We have included our website address is this prospectus supplement solely as an inactive textual reference.

<div align='center'>S-4</div>

TABLE OF CONTENTS

### THE OFFERING
Common stock offered by us

Shares of our Class A common stock having an aggregate offering price of up to $100,000,000.

Plan of distribution

“At the market offering” that may be made from time to time through our sales agent, Piper Sandler. See the section entitled “Plan of Distribution” on page S-13of this prospectus supplement.

Use of proceeds

We intend to use the net proceeds of this offering to advance the preclinical and clinical development of our product candidates and for working capital and other general corporate purposes. See the section entitled “Use of Proceeds” on page S-10of this prospectus supplement.

Risk factors

Investing in our securities involves risks. See “Risk Factors” beginning on page S-6of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in our Class A common stock.

Nasdaq Global Market symbol

“IMRX”

<div align='center'>S-5</div>

TABLE OF CONTENTS

### RISK FACTORS
Investment in any securities offered pursuant to this prospectus supplement and the accompanying base prospectus involves risks. You should carefully consider the risk factors described below and incorporated by reference to our Annual Report on Form 10-K and our quarterly reports on Form 10-Q and all other information contained or incorporated by reference in this prospectus supplement. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

#### Risks Relating to this Offering
If you purchase shares of our Class A common stock sold in this offering, you will experience immediate and substantial dilution in the net tangible book value